BCR-ABL SIGNALING A new STATus in CML

被引：0
|
作者：
Fabbro, Doriano [1 ]
机构：
[1] Novartis Inst Biomed Res, Basel, Switzerland
来源：
NATURE CHEMICAL BIOLOGY | 2012年 / 8卷 / 03期
关键词：
CHRONIC MYELOID-LEUKEMIA; BCR/ABL;
D O I：
10.1038/nchembio.900
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：228 / 229
页数：2
相关论文
共 50 条
  • [1] Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
    Burchert, Andreas
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2014, 9 (01) : 9 - 16
  • [2] Bcr-Abl inhibition as a modality of CML therapeutics
    Buchdunger, E
    Matter, A
    Druker, BJ
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01): : M11 - M18
  • [3] Frequency of BCR-ABL Transcript Types in Syrian CML Patients
    Farhat-Maghribi, Sulaf
    Habbal, Wafa
    Monem, Fawza
    JOURNAL OF ONCOLOGY, 2016, 2016
  • [4] Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
    Jabbour, Elias
    Saglio, Giuseppe
    Radich, Jerald
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (04) : 223 - 229
  • [5] Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
    Andreas Burchert
    Current Hematologic Malignancy Reports, 2014, 9 : 9 - 16
  • [6] Targeting of BCR-ABL: Lessons learned from BCR-ABL inhibition
    Lin, X.
    Qureshi, M. Z.
    Attar, R.
    Khalid, S.
    Tahir, F.
    Yaqub, A.
    Aslam, A.
    Yaylim, I.
    de Carlos Back, L. K.
    Farooqi, A. A.
    Ismail, M.
    CELLULAR AND MOLECULAR BIOLOGY, 2016, 62 (12) : 129 - 137
  • [7] CRKL binding to BCR-ABL and BCR-ABL transformation
    Kolibaba, KS
    Bhat, A
    Heaney, C
    Oda, T
    Druker, BJ
    LEUKEMIA & LYMPHOMA, 1999, 33 (1-2) : 119 - 126
  • [8] Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
    Brian J Druker
    Oncogene, 2002, 21 : 8541 - 8546
  • [9] CML: BCR-ABL Mutation Diagnostics and their Importance for the daily Treatment
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (06) : 416 - 416
  • [10] Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
    Druker, BJ
    ONCOGENE, 2002, 21 (56) : 8541 - 8546
12345